Global & Regional Health Technology Assessment最新文献

英文中文

Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy. 意大利 NYHA III 级心力衰竭患者接受 CardioMEMS 治疗的成本和收益。

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-05-02 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3018

Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli

Background: CardioMEMS is a device suitable for telemedicine that is currently being evaluated by the Regional Health Technology Assessment (HTA) Committee of Tuscany. Two detailed HTA reports are available in the specialized literature, the results of which need to be transferred to our regional setting. These decisions in Tuscany are made by the so-called Centro Operativo HTA.

Aim: To validate, with local cost-effectiveness data, the decision on CardioMEMS that will be made in the Tuscany region.

Methods: Two detailed international HTA reports were rearranged and adapted to our regional setting to generate a simplified analysis that could form the basis of our decision. Two willingness-to-pay (WTP) thresholds of €20,000/quality-adjusted life year (QALY) and €50,000/QALY were considered.

Results: Based on epidemiological and regulatory information, the target population in Tuscany for this device is 166 cases. The value-based price of CardioMEMS is estimated to be €4,332 and €16,662 at WTP thresholds of 20,000/QALY and 50,000/QALY, respectively. Its current price in Italy is €12,000.

Conclusion: In our region, the introduction of CardioMEMS is likely to be gradual, around 50 patients/year (or €0.60 million/year at current price). This example highlights the need to adapt the information published in the international literature to the local context in which the approval decision is made. In this context, simplified analyses are easier to apply than complex Markov models.

背景介绍CardioMEMS 是一种适用于远程医疗的设备，托斯卡纳地区卫生技术评估 (HTA) 委员会目前正在对其进行评估。专业文献中已有两份详细的 HTA 报告，其结果需要移植到我们的地区环境中。托斯卡纳的这些决定由所谓的 Centro Operativo HTA 做出。目的：利用当地的成本效益数据，验证托斯卡纳地区将做出的关于 CardioMEMS 的决定：对两份详细的国际 HTA 报告进行了重新编排，并根据我们的地区环境进行了调整，以生成一份简化的分析报告，作为我们决策的基础。我们考虑了两个支付意愿（WTP）阈值，分别为 20,000 欧元/质量调整生命年（QALY）和 50,000 欧元/质量调整生命年：根据流行病学和监管信息，该设备在托斯卡纳的目标人群为 166 例。根据价值估算，CardioMEMS 的价格分别为 4,332 欧元和 16,662 欧元，WTP 临界值分别为 20,000 欧元/QALY 和 50,000 欧元/QALY。其目前在意大利的价格为 12,000 欧元：在我们地区，CardioMEMS 的引入可能是渐进式的，大约每年 50 名患者（或按当前价格计算每年 60 万欧元）。这个例子强调了根据当地情况调整国际文献中公布的信息的必要性，因为当地情况决定是否批准。在这种情况下，简化分析比复杂的马尔可夫模型更容易应用。

{"title":"Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy.","authors":"Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli","doi":"10.33393/grhta.2024.3018","DOIUrl":"10.33393/grhta.2024.3018","url":null,"abstract":"Background: CardioMEMS is a device suitable for telemedicine that is currently being evaluated by the Regional Health Technology Assessment (HTA) Committee of Tuscany. Two detailed HTA reports are available in the specialized literature, the results of which need to be transferred to our regional setting. These decisions in Tuscany are made by the so-called Centro Operativo HTA.Aim: To validate, with local cost-effectiveness data, the decision on CardioMEMS that will be made in the Tuscany region.Methods: Two detailed international HTA reports were rearranged and adapted to our regional setting to generate a simplified analysis that could form the basis of our decision. Two willingness-to-pay (WTP) thresholds of €20,000/quality-adjusted life year (QALY) and €50,000/QALY were considered.Results: Based on epidemiological and regulatory information, the target population in Tuscany for this device is 166 cases. The value-based price of CardioMEMS is estimated to be €4,332 and €16,662 at WTP thresholds of 20,000/QALY and 50,000/QALY, respectively. Its current price in Italy is €12,000.Conclusion: In our region, the introduction of CardioMEMS is likely to be gradual, around 50 patients/year (or €0.60 million/year at current price). This example highlights the need to adapt the information published in the international literature to the local context in which the approval decision is made. In this context, simplified analyses are easier to apply than complex Markov models.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"105-107"},"PeriodicalIF":0.4,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11067868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dati regionali e loro ruolo nella pianificazione, nella programmazione e nel controllo a livello regionale. 地区数据及其在地区一级的规划、计划编制和控制中的作用。

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-04-25 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3024

Irene Marzona, Paolo Stella, Gianluca Trifirò, Giovanni Corrao

引用次数: 0

Prontuari Terapeutici Regionali in Italia: stato dell’arte e prospettive future. 意大利的地区治疗方案：技术水平和未来前景。

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-03-08 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2677

Alberto Bortolami, Claudio Jommi, Filippo Bresciani, Luca Piccoli, Elisa Sangiorgi, Giovanna Scroccaro

引用次数: 0

Costo per Number Needed to Treat (NNT) di upadacitinib nel trattamento dei pazienti bio-exposed con rettocolite ulcerosa attiva da moderata a grave. 奥达帕替尼治疗生物暴露的中重度活动性溃疡性直肠结肠炎患者的单位治疗人数成本（NNT）。

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-03-07 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2658

Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio

引用次数: 0

Regolamento HTA: come si sta muovendo l’Italia? HTA 法规：意大利在做什么？

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-03-05 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3025

Francesca Patarnello

引用次数: 0

Costo per NNT di upadacitinib nel trattamento dei pazienti con dermatite atopica da moderata a severa in Italia. 意大利奥达帕替尼治疗中重度特应性皮炎患者的每 NNT 成本。

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-02-16 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2728

Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio

引用次数: 0

Il burden clinico ed economico delle complicanze della cute peristomale: un’analisi di Activity Based Costing. 肛周皮肤并发症的临床和经济负担：基于活动成本的分析。

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-01-23 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2639

Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti

引用次数: 0

Il futuro delle forme di distribuzione dei farmaci in regime di Servizio Sanitario Nazionale. 国家医疗卫生服务机构药品配送形式的未来。

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2619

Massimo Medaglia, Giuliano Buzzetti, Marco Cossolo, Paola Deambrosis, Giovanna Scroccaro

引用次数: 0

Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP). 意大利因慢性肾病相关性瘙痒症（CKD-aP）而接受血液透析治疗的患者的医疗资源消耗情况。

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2696

Silvia Calabria, Lucio Manenti, Giulia Ronconi, Carlo Piccinni, Letizia Dondi, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini

Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, from the perspective of the Italian administrative healthcare data.

Methods: Through cross-linkage of Italian administrative healthcare data collected between 2015 and 2017 (accrual period) in the database of Fondazione ReS (Ricerca e Salute), patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of CKD-aP-related treatment (according to common clinical practice and guidelines) supplies and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (INHS).

Results: Of 1,239 people on hemodialysis for ≥2 years, CKD-aP affected 218 patients. Patients with CKD-aP were older and with more comorbidities. During the follow-up year, on average, the INHS spent €37,065 per case, €31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost.

Conclusions: This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP. Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP. The discovery of appropriate and effective treatments for this condition might offer cost offsets.

背景：慢性肾脏病相关性瘙痒症（CKD-aP）影响着血液透析患者。本研究从意大利行政医疗数据的角度出发，确定了可能受或不受 CKD-aP 影响的血液透析患者以及综合医疗成本：通过交叉链接 Fondazione ReS（Ricerca e Salute）数据库中收集的 2015 年至 2017 年（应计期）意大利行政医疗数据，筛选出接受院内/门诊血液透析的患者。根据有/无CKD-aP相关治疗（根据常见临床实践和指南）的供应情况，建立了有CKD-aP和无CKD-aP的队列，并对CKD-aP相关治疗和意大利国家卫生服务局（INHS）支付的人均医疗费用进行了评估：在 1239 名血液透析时间≥2 年的患者中，218 名患者患有 CKD-aP。CKD-aP患者年龄较大，合并症较多。在随访的一年中，INHS平均为每位患者花费了37065欧元，为每位对照组患者花费了31286欧元，为每位非CKD-aP患者花费了35988欧元。对 CKD-aP 血液透析患者进行的高效透析治疗在很大程度上影响了年平均总费用：这项真实世界研究发现了可能因 CKD-aP 而接受治疗的慢性血液透析患者。有趣的是，高效透析似乎是治疗 CKD-aP 最常见也是最昂贵的选择。发现治疗这种疾病的适当而有效的方法可能会抵消成本。

{"title":"Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP).","authors":"Silvia Calabria, Lucio Manenti, Giulia Ronconi, Carlo Piccinni, Letizia Dondi, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini","doi":"10.33393/grhta.2024.2696","DOIUrl":"10.33393/grhta.2024.2696","url":null,"abstract":"Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, from the perspective of the Italian administrative healthcare data.Methods: Through cross-linkage of Italian administrative healthcare data collected between 2015 and 2017 (accrual period) in the database of Fondazione ReS (Ricerca e Salute), patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of CKD-aP-related treatment (according to common clinical practice and guidelines) supplies and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (INHS).Results: Of 1,239 people on hemodialysis for ≥2 years, CKD-aP affected 218 patients. Patients with CKD-aP were older and with more comorbidities. During the follow-up year, on average, the INHS spent €37,065 per case, €31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost.Conclusions: This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP. Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP. The discovery of appropriate and effective treatments for this condition might offer cost offsets.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"22-30"},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Farmaci orfani in Italia: disponibilità e tempi di accesso a livello regionale. 意大利的 "孤儿药"：地区供应和获取时间。

IF 0.5 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment

Pub Date : 2023-12-28 eCollection Date: 2023-01-01 DOI: 10.33393/grhta.2023.2641

Maria Lucia Marino, Eva Alessi, Aurora Di Filippo, Barbara Polistena, Francesco Macchia, Federico Spandonaro, Francesco Trotta

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Global & Regional Health Technology Assessment

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀